SCHEMBL2986303

SCHEMBL2986303

CCC1C(=O)Nc2ccc(Cl)cc21

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.72
CDYL2 Q8N8U2 1/20 0.55
CDYL Q9Y232 1/20 0.55
TP53 P04637 4/20 0.42
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 2/20 0.41
HTR7 P34969 2/20 0.41
NQO2 P16083 3/20 0.41
CACNB4 O00305 1/20 0.41
CACNA1A O00555 1/20 0.41
CACNA1G O43497 1/20 0.41
CACNG3 O60359 1/20 0.41
CACNA1F O60840 1/20 0.41
CACNA1H O95180 1/20 0.41
CACNB3 P54284 1/20 0.41
CACNA2D1 P54289 1/20 0.41
CACNG7 P62955 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24754591 1.00 PGR (0.72) PGRCDYL2CDYLTP53MAPT
SCHEMBL25767723 0.87 PGR (0.63) PGRCDYL2CDYLHTR7CACNB4
SCHEMBL23835763 0.87 PGR (0.63) PGRCDYL2CDYLHTR7CACNB4
SCHEMBL5223844 0.84 PGR (1.00) PGRCDYL2CDYLHTR7
SCHEMBL2988866 0.81 PGR (0.57) PGRTP53MAPTPOLBLMNA
SCHEMBL24019919 0.81 PGR (0.57) PGRTP53MAPTPOLBLMNA
SCHEMBL16977576 0.81 IDO1 (0.62) PGRCDYL2CDYLTP53MAPT
SCHEMBL8303268 0.81 PGR (0.53) PGRCDYL2CDYLMEN1KMT2A
SCHEMBL2989569 0.80 TP53 (0.62) PGRTP53MAPTPOLBLMNA
SCHEMBL2320598 0.80 PGR (0.56) PGRCDYL2CDYLTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed
CN-1993324-B 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders EGYT GYOGYSZERVEGYESZETI GYAR 2010-12-15 CN disclosed
US-7786129-B2 Piperazine derivatives of dialkyl oxindoles EGIS GYOGYSZERGYAR NYRT (HU) 2010-08-31 US disclosed
CN-100572377-C The indol-2-one derivates of treatment nervus centralis obstacle, gastrointestinal disorders and cardiovascular disorder EGIS PHARMACEUTICAL WORKS (HU) 2009-12-23 CN disclosed
US-20090281137-A1 INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS VOLK BALAZS 2009-11-12 US disclosed
EP-1776339-B1 3-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS GYOGYSZERGYAR NYRT (HU) 2009-07-01 EP disclosed
EP-1751138-B9 INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS EGIS GYOGYSZERGYAR NYRT (HU) 2008-11-12 EP disclosed
EP-1751138-B1 INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS EGIS GYOGYSZERGYAR NYRT (HU) 2007-12-26 EP disclosed
US-20070232662-A1 Indol-2-One Derivatives for the Treatment of Central Nervous Disorders, Gastrointestinal Disorders and Cardiovascular Disorders EGIS GYOGYSZERGYAR RT. (HU) 2007-10-04 US disclosed
US-20070232619-A1 Piperazine Derivatives of Dialkyl Oxindoles EGIS GYOGYSZERGYAR RT. (HU) 2007-10-04 US disclosed
CN-101010313-A Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders EGIS PHARMACEUTICAL WORKS (HU) 2007-08-01 CN disclosed
CN-1993324-A 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders EGIS GYOGYSZERGYAR NYRT (HU) 2007-07-04 CN disclosed
EP-1776339-A2 3-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS Gyógyszergyár Nyrt (HU) 2007-04-25 EP disclosed
WO-2005109987-A9 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS GYOGYSZERGYAR NYRT (HU) 2007-03-29 WO disclosed
EP-1751138-A1 INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS EGIS Gyógyszergyár Nyrt (HU) 2007-02-14 EP disclosed
WO-2005109987-A2 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS GYÓGYSZERGYÁR NYRT. (HU) 2005-11-24 WO disclosed
WO-2005108390-A1 INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS EGIS GYÓGYSZERGYÁR NYRT. (HU) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232619-A1 Piperazine Derivatives of Dialkyl Oxindoles TPH2, DRD3, CNR2 PGR 2399/4885CDYL2 969/4885CDYL 646/4885
US-20070232662-A1 Indol-2-One Derivatives for the Treatment of Central Nervous Disorders, Gastrointestinal Disorders and Cardiovascular Disorders TPH2, TPH1, IDO1 PGR 2927/4885CDYL2 2057/4885CDYL 2545/4885
US-20090281137-A1 INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS TPH2, TPH1, IDO1 PGR 2991/4885CDYL2 2027/4885CDYL 2522/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL PGR 4195/4885CDYL2 2973/4885CDYL 2300/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV PGR 3910/4885CDYL2 2474/4885CDYL 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.